Protagonist Therapeutics (PTGX) Misses Q4 EPS by 10c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
March 12, 2019 4:01 PM EDTNEWARK, Calif., March 12, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the fourth quarter and full year ended December 31, 2018, and provided a corporate update on its clinical development programs.
"We continue to advance three different clinical development... More
